Øvrehus Marius A, Oldereid Tine S, Dadfar Aydin, Bjørneklett Rune, Aasarød Knut I, Fogo Agnes B, Ix Joachim H, Hallan Stein I
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Department of Nephrology, St. Olav Hospital, Trondheim University Hospital, Trondheim, Norway.
Kidney Int Rep. 2019 Dec 27;5(3):339-347. doi: 10.1016/j.ekir.2019.12.010. eCollection 2020 Mar.
Hypertensive nephrosclerosis is considered the second most common cause of end-stage renal disease (ESRD), but it is still an insufficiently studied and controversial disease entity. More information on the phenotype and prognosis is needed to improve clinical diagnostics and treatment.
We included all Norwegian patients with chronic kidney disease (CKD) referred for kidney biopsy between 1988 and 2012 whose clinical presentation was consistent with, but not primarily suspicious for, hypertensive nephrosclerosis (n = 4920); follow-up continued until 2013.
A total of 918 patients (19%) had biopsy-verified hypertensive nephrosclerosis (i.e., arterionephrosclerosis). Their most common biopsy indications were proteinuria (57%), low estimated glomerular filtration rate (eGFR) (44%), hematuria (34%), or combinations of these indications. Multivariable logistic regression analysis revealed that arterionephrosclerosis was significantly associated with higher age, male sex, not having diabetes, higher blood pressure, lower proteinuria, and not having hematuria ( < 0.01 for all). Body mass index, cholesterol, high-density lipoprotein cholesterol, and eGFR were not significantly associated with arterionephrosclerosis ( > 0.05 for all). The most common biopsy-verified diagnoses in patients fulfilling the clinical criteria for hypertensive nephrosclerosis were arterionephrosclerosis (40%), glomerulonephritis (22%), and interstitial nephritis (14%), reflecting that the criteria had low sensitivity (0.17) and high specificity (0.94). ESRD and mortality risks did not differ in patients with arterionephrosclerosis compared to patients with glomerulonephritis, interstitial nephritis, or other relevant diagnoses ( > 0.1 for both), whereas patients with diabetic kidney disease had a 2-fold higher risk ( < 0.001 for both).
Arterionephrosclerosis is a high-risk disease, often with an atypical phenotype with proteinuria and hematuria contributing to low accuracy for current clinical criteria for hypertensive nephrosclerosis.
高血压性肾硬化被认为是终末期肾病(ESRD)的第二大常见病因,但它仍是一个研究不足且存在争议的疾病实体。需要更多关于其表型和预后的信息来改善临床诊断和治疗。
我们纳入了1988年至2012年间所有因临床表现符合但并非主要怀疑为高血压性肾硬化而转诊进行肾活检的挪威慢性肾脏病(CKD)患者(n = 4920);随访持续至2013年。
共有918例患者(19%)经活检证实为高血压性肾硬化(即动脉性肾硬化)。他们最常见的活检指征是蛋白尿(57%)、估计肾小球滤过率(eGFR)低(44%)、血尿(34%)或这些指征的组合。多变量逻辑回归分析显示,动脉性肾硬化与年龄较大、男性、无糖尿病、血压较高、蛋白尿较低和无血尿显著相关(所有P均<0.01)。体重指数、胆固醇、高密度脂蛋白胆固醇和eGFR与动脉性肾硬化无显著相关性(所有P均>0.05)。符合高血压性肾硬化临床标准的患者中,经活检证实的最常见诊断是动脉性肾硬化(40%)、肾小球肾炎(22%)和间质性肾炎(14%),这表明该标准敏感性低(0.17)而特异性高(0.94)。与肾小球肾炎、间质性肾炎或其他相关诊断的患者相比,动脉性肾硬化患者的ESRD和死亡风险无差异(两者P均>0.1),而糖尿病肾病患者的风险高2倍(两者P均<0.001)。
动脉性肾硬化是一种高危疾病,其表型通常不典型,蛋白尿和血尿导致目前高血压性肾硬化临床标准的准确性较低。